… DFS at 3 years. This study failed to meet its prespecified primary end points, which was not
surprising as retrospective studies have shown only a 5% survival advantage at 5 years. An …

… The 5 year survival rate is approximately 15–30% [2, 18]. Although some clinical trials have
used consolidation chemotherapy after standard CCRT, they have still failed to prolong the …

… Lung cancer survival varies greatly depending on the stage of the … non-small cell lung cancer
(NSCLC) TNM groupings, 5-year survival estimates in NSLCC ranged from 73% in stage IA …

… More specifically, up to 30% of patients with stage I NSCLC will die within 5 years of surgery.
… patients with early-stage NSCLC who may benefit from additional treatment after surgery. …

… Stage III non-small cell lung cancer (NSCLC) includes a highly heterogeneous group of … in
the treatment of NSCLC have succeeded in increasing overall survival at 5 years of diagnosis …

… years, treatment options for patients diagnosed with advanced non–small cell lung cancer
(NSCLC) were limited to cytotoxic chemotherapies, which conferred a median overall survival (…

… The International Association for the Study of Lung Cancer Staging Project: prognostic
factors and pathologic TNM stage in surgically managed non-small cell lung cancer.  …

… treatment and overall survival (OS) of German patients with a diagnosis of advanced non-small
cell lung cancer (… ), and to explore factors associated with the real-world mortality risk. …

… risk of 5-year overall survival in early-stage cancers. Procedures to … 5-year overall survival
because studies have shown that in early-stage NSCLC, 5-year and 10-year overall survival …

… end points were progression-free survival (PFS; time from random assignment to documented
PD or death due to any cause) and objective response rate (proportion of patients with …